McKesson Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended December 31, 2023 (fiscal Q3 and first nine months of fiscal 2024; fiscal year ends March 31). Comparisons are with the corresponding prior-year periods. McKesson operates U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International segments. Amounts below are U.S. dollars.
Financial performance
| Metric | Three months ended Dec. 31, 2023 | Prior year | Nine months ended Dec. 31, 2023 | Prior year |
|---|---|---|---|---|
| Revenue | $80.898 billion | $70.490 billion | $232.596 billion | $207.801 billion |
| Gross profit / margin | $3.152 billion / 3.90% | $3.174 billion / 4.50% | $9.243 billion / 3.97% | $9.292 billion / 4.47% |
| Operating income | $642 million | $1.241 billion | $2.693 billion | $3.401 billion |
| Net income attributable to McKesson | $589 million | $1.079 billion | $2.211 billion | $2.773 billion |
| Diluted continuing-operations EPS | $4.42 | $7.65 | $16.39 | $19.32 |
| Operating cash flow | Not separately presented for the quarter | $167 million | $1.834 billion |
- Quarterly revenue increased 15%, but gross profit fell 1%; gross margin contracted 60 basis points. Nine-month revenue rose 12%, while gross profit declined 1% and margin fell 50 basis points.
- Quarterly operating expenses rose 30%, to $2.510 billion, largely reflecting a $515 million Rite Aid bad-debt provision. Nine-month operating expenses increased 11%, to $6.550 billion; the nine-month Rite Aid provision was $725 million.
- Nine-month operating cash flow fell to $167 million from $1.834 billion. Working-capital movements included increases of $4.298 billion in receivables and $2.384 billion in inventory, partly offset by a $4.163 billion increase in accounts payable; opioid-settlement payments reduced cash by $529 million.
- Nine-month investing cash outflow was $495 million and financing cash outflow was $2.374 billion. Cash and cash equivalents were $1.982 billion at December 31, 2023, down from $4.678 billion at March 31, 2023.
- Total debt was $5.673 billion, including $218 million of short-term borrowings; long-term debt was $5.625 billion. The $4.0 billion revolving credit facility was undrawn, and the company reported compliance with its covenants. Working capital was negative $4.021 billion; the reported debt-to-capital ratio was 126.7%.
Material changes and segment results
- U.S. Pharmaceutical revenue grew 18% in the quarter and 17% for nine months, driven by market growth, specialty pharmaceuticals, and retail-account volumes. Segment operating profit fell 64% for the quarter and 29% for nine months, principally due to Rite Aid credit provisions, alongside other comparative-period and operating-cost effects.
- RxTS revenue increased 7% in the quarter and 12% for nine months. Operating profit rose 31% and 62%, respectively, supported by access-services growth; nine-month results also included a $78 million gain from remeasurement of Rx Savings Solutions contingent consideration.
- Medical-Surgical Solutions revenue increased 2% in the quarter and 1% for nine months, while operating profit fell 18% and 16%. Management cited lower COVID-19 vaccine ancillary-supply activity and, for nine months, higher costs supporting growth.
- International revenue declined 18% in the quarter and 39% for nine months, mainly because of the prior-year E.U. business divestiture, partly offset by growth in Canada. Nine-month segment operating profit increased from the prior-year comparison, which included E.U. divestiture remeasurement charges.
- Prior-year consolidated results included significant gains—notably $126 million from early termination of a tax receivable agreement, $97 million from terminating interest-rate swaps, and a $142 million investment-exit gain in the nine-month period. Their absence weighed on current-period comparisons.
Outlook, commentary, risks, and unusual items
- The filing provides no numerical earnings or revenue guidance. Management said cash generation, existing liquidity sources, and access to capital markets should be sufficient for foreseeable funding needs. It anticipated approximately $125 million of total restructuring charges; $101 million had been recorded through December 31, 2023, with the program expected to be substantially complete by fiscal year-end.
- Opioid-related governmental and tribal settlement liabilities totaled $6.644 billion at December 31, 2023, of which $516 million was current. McKesson had paid approximately $1.5 billion under the multistate settlement and expects further payments under settlement agreements through 2038. The company says it cannot estimate potential losses for many other opioid claims; adverse outcomes could materially affect results, cash flows, or liquidity.
- Rite Aid’s October 2023 Chapter 11 filing led to $725 million in nine-month bad-debt provisions. McKesson considers its reserves appropriate but says it will reassess them as circumstances warrant.
- The IRS proposed $600–$700 million of additional federal tax for fiscal 2018 and 2019. McKesson disputes the proposed adjustments, is pursuing the administrative process, and says it has adequately reserved; resolution is not expected within the next 12 months. An adverse outcome could materially affect future financial position, results, and cash flows.
- A Ninth Circuit ruling affirmed partial summary judgment that certain opioid-litigation defense costs were not covered by two insurer policies. The company also flagged a comparatively higher risk of material goodwill impairment at McKesson Canada, though fiscal 2024 annual testing found no goodwill impairment.
- Quarterly results included a $141 million net discrete tax benefit, including a $154 million valuation-allowance release; the nine-month period also included a $147 million discrete tax benefit related to an intra-company intellectual-property transfer. These tax items materially affected reported tax rates.
- McKesson repurchased $2.347 billion of shares and paid $232 million in dividends during the nine months. It raised the quarterly dividend to $0.62 per share and had $7.3 billion remaining under its repurchase authorization. Future dividends remain at the Board’s discretion.
Most important facts for investors to verify
- Rite Aid bankruptcy recoveries, remaining receivable exposure, and any changes to bad-debt reserves.
- Cash conversion and working-capital trends, especially receivables, inventory, and supplier-payable movements.
- Opioid settlement payment schedule, adequacy of recorded liabilities, and developments in uninsured or otherwise unsettled claims.
- Outcome and reserve assumptions for the IRS dispute involving the proposed $600–$700 million tax adjustment.
- Whether U.S. Pharmaceutical profitability recovers and whether RxTS growth offsets pressure in other segments.
- Execution and remaining cost of the restructuring program, and the company’s continued capacity to fund debt, litigation payments, dividends, and repurchases.